Clinical trial · Interventional
Microtransplantation in Older Patients With Acute Myeloid Leukemia
International Multi-center Clinical Study on Microtransplantation for Treatment of Newly Diagnosed Elderly Acute Myeloid Leukemia (EAML)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to see whether HLA-mismatched donor cells infusion with chemotherapy (microtransplantation,MST) could increase complete remission (CR) and improve survival in older patients with acute myeloid leukemia (AML),the investigators conducted a prospective, multicenter clinical trial of HLA-mismatched MST to estimate outcomes and toxicities.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Myeloid Leukemia | Acute Myeloid Leukemia | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| microtransplantation | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- MST(microtransplantation)
- interventionNames
- Biological: microtransplantation
Primary outcomes (1)
- measure
- Graft versus host disease
- timeFrame
- 1 month
Secondary outcomes (3)
- measure
- overall survival
- timeFrame
- 2 years
- measure
- leukemia free survival
- timeFrame
- 2 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 60 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: * de novo acute myeloid leukemia * age 60-90 * have HLA mismatched donor Exclusion Criteria: * have no suitable donor or donor refused * patient refused to accept donor cells
References
Publications (0)
Data not yet available